Quang X. Pham - 23 Jan 2025 Form 4/A - Amendment Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Reporting relationship: CEO and Chairman, Director, 10%+ Owner
Issuer ticker: CVKD
Reported as of: 23 Jan 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 24 Mar 2025, 20:38:14 UTC
Original report date: 24 Jan 2025
Prior SEC filing: 10 Apr 2024
Next SEC filing: 29 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew K. Szot, Attorney-in-fact

Key filing fact

Quang X. Pham filed Form 4/A - Amendment for Cadrenal Therapeutics, Inc. (CVKD) on 24 Mar 2025.

Key facts

This page summarizes Quang X. Pham's Form 4/A - Amendment filing for Cadrenal Therapeutics, Inc. (CVKD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Mar 2025, 20:38.

Change

Previous filing in this sequence was filed on 10 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CVKD transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +65,000
Change %
Price: $0.000000
Shares after: 65,000
Date: 23 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $19.79
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This amendment to Form 4 is being filed to correct the exercise price and the expiration date of the stock option, which were incorrectly reported on the original Form 4 filed by the Reporting Person on January 24, 2025 (the "Original Form 4"). The exercise price of the stock option is equal to 100% of the fair market value of the Issuer's common stock on the effective date of the grant and the stock option expires ten years from the date of issuance. The stock option vests according to the vesting schedule as previously reported on the Original Form 4.